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Yasuo Mori,1,2 Toshihiro Miyamoto,1 Koji Nagafuji,1 Kenjiro Kamezaki,1 Asataro Yamamoto,1
Noriyuki Saito,1,2 Koji Kato,1 Katsuto Takenaka,1 Hiromi Iwasaki,2 Naoki Harada,1
Yasunobu Abe,3 Takanori Teshima,2 Koichi Akashi1,2Human herpes virus (HHV)6-associated limbic encephalitis and/or myelitis is one of the life-threatening cen-
tral nervous system complications following allogeneic hematopoietic stem cell transplantation (HSCT). Re-
cent reports have shown significant correlations of these complications with unrelated cord blood
transplantation (UCBT). We retrospectively analyzed 228 allogeneic HSCT recipients in our single institu-
tion; 13 patients (5.7%) were diagnosed with HHV6-associated encephalitis/myelitis. This complication
was documented in 8 of 51 UCBT recipients (15.7%) and 5 of 177 recipients (2.8%) transplanted with
bone marrow or peripheral blood stem cells, indicating a higher incidence of this complication occurring
in UCBTrecipients (P5.0005). In addition, HHV6-associated encephalitis/myelitis occurred more frequently
in recipients who underwent 2 ormoreHSCTs (7 of 59 recipients [11.9%]), compared to thosewho received
only 1 HSCT (6 of 169 recipients [3.6%], P5 .018). Of note, the incidence of this complication increased to
28.6% (6 of 21 recipients), when the analysis was restricted to a second or more UCBT recipients. All 13
patients presented preengraftment immune response prior to the onset of encephalitis. Two patients man-
ifested typical symptoms at the onset of HHV6-associated encephalitis/myelitis, such as memory dysfunction,
disorientation, and consciousness disturbance. However, 4 patients presented only with dysesthesia and
pruritus, described as typical manifestations of patients with calcineurin-inhibitor-induced pain syndrome
(CIPS), and the remaining 7 showed both symptoms, indicating that CIPS-like symptoms might be manifes-
tations of HHV6-associated myelitis. Thus, physicians should be alert to this rare but often fatal complication,
particularly for those who receive 2 or more HSCTs using UCB.
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Human herpes virus (HHV)6 causes roseola infan-
tum in infants, acute nonspecific febrile illness in
younger children, and can give rise to an infectious
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6/j.bbmt.2010.05.009can be reactivated under conditions of severe immuno-
suppression, and is recognized as an opportunistic and
potentially life-threatening pathogen for allogeneic
hematopoietic stem cell transplantation (HSCT) recip-
ients [2-8]. Many investigators have reported various
clinical manifestations of HHV6 reactivation in the
central nervous system (CNS), such as short-term
memorydysfunction, disorientation, consciousness dis-
turbance, hyponatremia [6,9], or diabetes insipidus [10].
Diagnosis of these complications in the CNS can be
made using specific techniques, such as abnormal
high-intensity signals in bilateral temporal lobes (limbic
area) on T2-weightned and/or fluid-attenuated inver-
sion recovery sequences from magnetic resonance
imaging (MRI), and detection of HHV6 DNA in the
cerebrospinal fluid (CSF) by the polymerase chain
reaction (PCR) method.
Recent reports have suggested that HHV6 reacti-
vation is more likely to occur in recipients of unrelated
cord blood transplantation (UCBT) than in those who
Biol Blood Marrow Transplant 16:1596-1602, 2010 1597HHV-6 Encephalitis/Myelitis after the Second UCBTreceive allogeneic bone marrow transplantation
(BMT) or peripheral blood stem cell transplantation
(PBSCT) [6,11,12]. These findings may be because
of the absence of primed HHV6-specific T cells and
the immunologic immaturity of UCBT [11-14].
Because of the increasing preference for UCBT
procedures because of the rapid availability of stored
transplantable units, we should pay more attention to
HHV6-associated encephalitis/myelitis for UCBT
procedures.
In this study, we described 13 patients with
HHV6-associated encephalitis/myelitis among 228
allogeneic HSCT recipients. We found a higher inci-
dence of HHV6-associated encephalitis/myelitis for
UCBT recipients (8 of 51, 15.7%) than for BMT
and PBSCT recipients (5 of 177, 2.8%, P 5 .0005).
In addition, the incidence of HHV6-associated en-
cephalitis/myelitis increased to 28.6% for recipients
who received 2 or more UCBTs (6 of 21). We also
identified the factors associated with the onset of
HHV6-associated encephalitis/myelitis in this study.PATIENTS AND METHODS
Patients
The medical records of all patients who underwent
allogeneic HSCT at the Kyushu University Hospital
between January 2002 and October 2009 were re-
viewed. A total of 228 patients (136 men, 92 women)
(median age5 47 years), were studied. Patients’ charac-
teristics are listed in Table 1. Primary diseases included
myelodysplastic syndrome (MDS)/acute myelogenous
leukemia (AML) (n5 92), chronic myelogenous leuke-
mia (CML) (n 5 13), acute lymphoblastic leukemia
(ALL) (n 5 31), malignant lymphoma (ML) (n 5 57),
aplastic anemia (AA) (n5 14), and others (n5 21). A to-
tal of 101 cases were considered early state defined as
follows: acute leukemia (AML and ALL) in remission;
CML in chronic phase (CP); MDS classified as refrac-
tory anemia (RA) or RA with ringed sideroblasts. All
others (n 5 127) were considered as nonearly state.
This study was approved by the institutional review
board of Kyushu University Hospital.Transplantation Procedures
A total of 133 patients had received conventional
preparative regimens comprised of either total body
irradiation (TBI)/cyclophosphamide (Cy) (n 5 91), or
busulfan (Bu)/Cy (n 5 42) (Table 1). The remaining
95 cases had received purine analog-based reduced-in-
tensity conditioning (RIC) regimen comprised of either
fludarabine (Flu)/Cy (n5 16), Flu/Bu (n5 48), or Flu/
melphalan (n 5 31). Low-dose TBI (2-4 Gy),
antithymocyte globulin (ATG), and alemutuzumab
were administered in 49, 3, and 3 cases, respectively.The sources of stem cells were related granulocyte
colony-stimulating factor (G-CSF)-mobilized PB (n
5 71), related BM (n 5 15), unrelated BM (n 5 91),
or unrelated CB (n 5 51). HLA-matching varied from
haploidentical (3/6) to identical (6/6). A total of 59 re-
cipients had received 2 or more HSCTs as listed in
Table 1: the source of stem cells for the first transplant
were 24 autologous and35 allogeneic ones.The reasons
for a second or more HSCT were disease relapse (n 5
50) and graft failure (n 5 9). Graft-versus-host-disease
(GVHD) prophylaxis was as follows: 20 received
calcineurin-inhibitor (CI) alone; 193 received CI plus
short-term methotrexate (MTX); and 15 received CI
plus mycophenolate mofetil (MMF).Diagnosis of HHV6-Associated Encephalitis/
Myelitis
HHV6-associated encephalitis/myelitis was di-
rectly proved when HHV6 viral DNA was detected
in the CSF, as previously reported [15]. For those pa-
tients who were unable to undergo lumbar puncture
because of severe thrombocytopenia or a deteriorated
general condition, we diagnosed HHV6-associated
encephalitis/myelitis if they satisfied more than 2 of
the following 3 criterion: (1) typical clinical manifesta-
tions; (2) detection of HHV6 viral DNA in PB, previ-
ously reported as a predictive marker for developing
HHV6-associated encephalitis/myelitis [16]; or (3)
limbic encephalopathy based on the selective involve-
ment of the medial temporal lobe on MRI. Routine
monitoring of HHV6 viral load of PB by PCR was
not performed in this study.Statistical Analysis
The aim of this study is to clarify the factor corre-
lated with developing HHV6-associated encephalitis/
myelitis. For univariate comparisons, we examined
categoric variables, including age, sex, underlying dis-
eases, disease status, conditioning regimen, stem cell
source, HLAmatching, GVHD prophylaxis, and prior
HSCT using the chi-square test. The incidence of
HHV6-associated encephalitis/myelitis is generally
very low. The risk of type 1 error has been known to
increase when the event per variable is\10; we nar-
rowed an analysis to 1 risk factor selected by 22 log
likelihood method to avoid it. Odds ratios were
calculated using logistic regression analysis. Survival
following allogeneic HSCT was measured from the
date of stem cell infusion until the date of death. The
survival period was calculated using the Kaplan-
Meier method. P-values\ .05 were considered to indi-
cate statistical significance. All statistical analyses used
SPSS 17.0 program (SPSS Japan Inc., Tokyo, Japan).
Table 1. Characteristics of the 228 Patients
HHV6 Encephalitis/Myelitis
Characteristics Total
Yes
(n 5 13)
No
(n 5 215) P-value
Age, median (range) 47 (16-68) 48 (29-65) 47 (16-68) NS
Sex (male/female) 136/92 10/3 126/89 NS
Underlying disease NS
MDS/AML 92 7 85
CML 13 0 13
ALL 31 1 30
ML 57 4 53
AA 14 1 13
Others 21 0 21
Disease status
at transplantation
NS
Early* 101 4 97
Nonearly 127 9 118
Conditioning regimen .038
Conventional 133 4 129
Reduced-intensity 95 9 86
Stem cell source .0005
Related PB 71 2 69
Related BM 15 0 15
Unrelated BM 91 3 88
Unrelated CB 51 8 43
Times and sources
of HSCT
.018
First 169 6 163
non-UCB 139 4 135
UCB 30 2 28
Second / first source 55 6 49
non-UCB / Auto 18 1 17
/ non-UCB 14 0 14
/ UCB 4 0 4
UCB / Auto 4 0 4
/ non-UCB 7 4 3
/ UCB 8 1 7
Third / second source 4 1 3
Non-UCB / Auto 1 0 1
/ non-UCB 1 0 1
UCB/ non-UCB 2 1 1
HLA matching .012
#4/6 52 6 46
5/6 47 4 43
6/6 129 3 126
GVHD prophylaxis <.0001
CI alone 20 2 18
CI plus sMTX 193 5 188
CI plus MMF 15 6 9
IgG-antibody for
HHV6 (titer)
NS
negative 0 0 0
10-20 45 3 42
40-80 125 7 118
160- 26 1 25
unknown 32 2 30
CI indicates calcineulin-inhibitor, including cyclosporine and tacrolimus;
NS, not significant; CML, chronic myelogenous; MDS/AML, myelodys-
plastic syndrome/acute myelogenous leukemia; ALL, acute lymphoblas-
tic leukemia; ML, malignant lymphoma; AA, aplastic anemia; MTX,
methotrexate; MMF, mycophenolate mofetil; PB, peripheral blood;
BM, bone marrow; CB, cord blood, HSCT, hematopoietic stem cell
transplantation; UCB, unrelated CB; GVHD, graft-versus-host disease;
non-UCB included related PB, related BM, and unrelated BM.
*Early stage is defined as: acute leukemia in remission; CML in chronic
phase; MDS classified as refractory anemia or refractory anemia with
ringed sideroblasts; lymphoma in remission. All others are considered
nonearly stage.
1598 Biol Blood Marrow Transplant 16:1596-1602, 2010Y. Mori et al.RESULTS
Incidence of HHV6-Associated Encephalitis/
Myelitis
In our series, a total of 13 patients among 228 allo-
geneic HSCT recipients (5.7%) developed HHV6-
associated encephalitis/myelitis after allogeneic HSCT.
Median onset was 23 days after transplantation, in
line with the previous multicenter retrospective re-
search in Japan [17]. HHV6 viral DNA was detected
in CSF samples of 9 patients, whereas the remaining
4 were diagnosed with HHV6-associated encephali-
tis/myelitis by satisfying the criteria for clinical features
andMRI findings (n5 1), clinical features and PCR as-
say of PB (n5 2), or all 3 criteria (n5 1). There was no
statistical difference among the underlying diseases. A
previous report has demonstrated a close association
between a lower titer of anti-HHV6 IgG (\40) and
development of HHV6 reactivation [14], however,
in our study, there was no significant relationship
between them (Table 1).
Seven of 59 (11.9%) patients who underwent 2 or
more HSCTs developed HHV6-associated encephali-
tis/myelitis, which was significantly more frequent
than in the 6 of 169 (3.6%) patients who received a first
HSCT (P 5 .018). A high incidence of HHV6-
associated encephalitis/myelitis was also found in
patients who received UCBT compared to those who
received a non-UCBT (8 of 51, 15.7% versus 5 of 177,
2.8%: P 5 .0005). Moreover, the incidence of HHV6-
associated encephalitis/myelitis increased to 28.6% (6
of 21), when the analysis was restricted to those patients
who received a second or more UCBT, which was sig-
nificantly more frequent than those who received a sec-
ond non-UCBT (1 of 38; P 5 .003). Patients who
receivedHSCTs fromHLA-mismatched donors devel-
oped HHV6-associated encephalitis/myelitis more fre-
quently than thosewithHLA-matcheddonors (10of 99,
10.1%versus 3 of 129, 2.3%;P5 .012).Thismay reflect
the fact thatmostUCBT recipients received transplants
using HLA-mismatched cord blood. We also found
a relatively high incidence ofHHV6-associated enceph-
alitis/myelitis in those patients who underwent Flu-
based RIC (9 of 95) or CI and MMF for the prevention
of GVHD (6 of 15), as UCBT recipients preferentially
received RIC and GVHD prophylaxis with CI and
MMF in our institution.Clinical Features of HHV6-Associated
Encephalitis/Myelitis
Clinical and laboratory findings for the 13 patients
at the onset of HHV6-associated encephalitis/myelitis
are shown in Table 2. The median onset of clinical
symptoms was 23 days (range: 14-614 days). Symp-
toms occurred within 10 days of their neutrophil en-
graftments (.0.5  109/L) in 10 patients, whereas
Biol Blood Marrow Transplant 16:1596-1602, 2010 1599HHV-6 Encephalitis/Myelitis after the Second UCBTthe remaining 3 patients developed clinical manifesta-
tions more than 10 days after their engraftments. Prior
to the onset of HHV6-associated encephalitis/myeli-
tis, immunosuppressive treatments had commenced
for 7 patients which comprised of .1 mg/kg of meth-
ylprednisolone against GVHD or hemophagocytic
syndrome (HPS).
The cardinal features ofHHV6-associated enceph-
alitis are well documented: short-term memory dys-
function, disorientation, consciousness disturbance,
and seizures [2-7]. In our study, these typical
symptoms were found in 2 of the 13 patients, whereas
4 developed only systemic pruritus with no apparent
skin rash and intermittent pain in the extremities,
which were similar to the reported manifestations of
CI-induced pain syndrome (CIPS) [18,19]. Both
encephalitis and CIPS-like symptoms were found in
the remaining 7 patients.
Positive results for headMRI scans (limbic enceph-
alitis) were observed in 7 of 9 patients (77.8%) who de-
veloped encephalitis-type symptoms, which were not
found in the 4 patients who only had CIPS-like symp-
toms; only 1 presenting with CIPS-like symptoms had
positive results for spinal MRI. Interestingly, all pa-
tients who developed HHV6-associated encephalitis/
myelitis had noninfectious fevers before their engraft-
ments known as a ‘‘preengraftment immune reaction’’
(PIR) or ‘‘hyperacute GVHD’’ [13,20], and 3 of them
subsequently developed HPS (shown in Table 2).
HHV6 viral DNA was detected in CSF samples of
all 9 patients who were assessed. The viral copy levels
varied from 2  102 to 2  105 copies/mL (Table 2):
however, these did not correlate with the degree of
sequelae or the presence of definite abnormal findings
on MRI.Treatment and Outcomes
Nine of 13 patients were treated with antiviral
combination therapy using gancyclovir (GCV; 5-10
mg/kg/day) and foscarnet (FCV; 60-180 mg/kg/day).
Monotherapy with FCV was initiated for 2 patients,
ACV for 1, and GCV for the other. Clinical features
were relieved in all but 1 patient treated with GCV
plus FCV. However, mild neurologic sequelae re-
mained in all 3 survivors, such as memory impairment,
CIPS-like dysesthesia, dysuria, or dyschezia (Table 2).
Ten patients died thereafter; the causes included
HHV6-associated encephalitis (n5 1), disease progres-
sion (n 5 4), GVHD (n 5 2), infection (n 5 2), and
donor-derived secondary MDS (n 5 1). In our study,
the 5-year survivals after HSCT were 17.3% 6 14.6%
for the patients with HHV6-associated encephalitis/
myelitis, and 37.2% 6 3.9% for the patients without
this complication. Although no significant difference
in survival was noted (P 5 .31), patients with HHV6-associated encephalitis/myelitis tended to have poorer
outcomes, as previously reported [21,22].
Risk Factors for HHV6-Associated Encephalitis/
Myelitis
Fromtheunivariate analysisusing logistic regression,
HHV6-associated encephalitis/myelitis were strongly
associated with the stem cell source (CBT versus others;
P\0.001).Multivariate analysis confirmed that a second
or more UCBTwas the only independent risk factor for
HHV6-associated encephalitis (odds ratio5 13.58; 95%
confidence interval5 3.45-53.5; P\.001) (Table 3).DISCUSSION
A second HSCT may be the only way to ensure
survival in some patients with hematologic malignan-
cies that relapse after the first HSCT. UCB has be-
come increasingly preferred as the source of graft for
a second HSCT because of the rapid availability of
stored transplantable units. However, using UCB
presents an increased risk of graft failure and infectious
complications. HHV6-associated encephalitis/myeli-
tis is one of the most life-threatening CNS complica-
tions after UCBT. In this study, HHV6-associated
encephalitis/myelitis occurred more frequently for
UCBT recipients (15.7%) compared to BMT and
PBSCT recipients (2.8%), and the incidence of
HHV6-associated encephalitis/myelitis increased to
28.6% for recipients who received 2 or more UCBTs,
although this observation should be interpreted with
caution and confirmed in a prospective study because
of the limited number of patients. We should also
pay attention to the possibility that this result might
reflect the selection bias; the patients requiring a sec-
ond UCBT had more aggressive disease than those
who require second non-UCBT and were, by nature,
more susceptible to various infections including
HHV6 reactivation. In addition to the absence of
primed HHV6-specific T cells with UCBT, the high
incidence of HHV6-associated encephalitis/myelitis
after 2 or more UCBTs may be explained by a pro-
longed immune deficiency caused by multiple HSCTs
as well as by HLA mismatches between donors and
recipients [11-14]. CMV antigen tests were positive
in 10 of 13 patients with HHV6-associated encephali-
tis/myelitis (data not shown), which might also suggest
the impaired immune function as well. In our study,
the all-cause mortality within 100 days for second or
more UCBT recipients who developed this complica-
tion reached 50%, indicating that HHV6-associated
encephalitis/myelitis is a common serious problem,
especially following a second or more UCBT.
Several reports have found that PIR often preceded
engraftment and that HPS frequently co-occurred in
those UCBT recipients who were treated with RIC
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1600 Biol Blood Marrow Transplant 16:1596-1602, 2010Y. Mori et al.(RIC-UCBT), and that PIR and HPS were character-
ized by symptoms possibly induced by hypercytokine-
mia [23-25]. In the setting of RIC-UCBT, an HLA
disparity as well as residual recipients’ immuno compe-
tent cells may augment allo-immune mediated events,
such as pro-inflammatory cytokine storms, which result
in the development of PIR and/or HPS [6,23-25]. Our
study also demonstrated that RIC-UCBT recipients
developed PIR more frequently (23 of 31, 74.2%)
than UCBT recipients who underwent conventional
conditioning (5 of 20, 25%). Several investigators
have also found a higher incidence of HHV6-
associated encephalitis/myelitis that has been docu-
mented for RIC-UCBT recipients with complications
like PIR or HPS [6,25]. In fact, in our study, all 13
patients with HHV6-associated encephalitis/myelitis
had suffered from PIR prior to the onset of encephalo-
pathy, and 3 of them subsequently developed severe
HPS. In contrast, among 43 UCBT recipients who
did not develop HHV6-associated encephalitis/myeli-
tis, PIR and HPS were observed less frequently in 20
(46.5%) and0 (0%), respectively, indicating that the de-
velopment of HHV6-associated encephalitis/myelitis
might be closely associated with PIR or HPS. In line
with our observations, Ogata et al. [26] recently re-
ported that episodes of PIRorGVHDwere closely cor-
related with the development of HHV6-associated
encephalitis. In addition, they also demonstrated a sig-
nificant increase of serum interleukin (IL)-6 levels, par-
ticularly in those patients precedingHHV6reactivation
and progression to encephalopathy, suggesting that
a high IL-6 level might be critical for the development
of HHV6-associated encephalitis/myelitis. Several re-
ports previously demonstrated high levels of IL-6 in
the sera and cerebral spinal fluids of patients with asep-
tic meningitis/encephalitis, indicating the possible par-
ticipation of IL-6 in the pathogenesis of meningitis/
encephalitis [27-29]. The contributions of IL-6 to the
development of meningitis/encephalitis may include
epithelial and endothelial injuries, increased permeabil-
ity in the blood-brain barrier, or apoptosis in the cere-
brum resulting from a hyper immune reaction
[26,30,31]. We also observed increased levels of IL-6
in the majority of the patients with PIR (unpublished
data). Thus, PIR or HPS may augment excessive im-
mune reactions when combined with these observa-
tions, such as high IL-6 secretion, which partially
contribute to the subsequent development of HHV6-
associated encephalitis/myelitis.
CIPS is a newly established disease entity that is
characterized by severe pain, typically in the lower
limbs. CIPS is hypothesized to result from
calcineurin-induced vascular changes that disturb
bone perfusion and permeability, which leads to
intraosseous vasoconstriction and BM edema [18,19].
This rare syndrome has been described in organ
transplant recipients [32-35], where CIs must be
Table 3. Results of a Logistic Regression Analysis
Univariate Multivariate (stepwise)
Characteristics
Odds Ratio (95%
Confidence Interval) P-Value
Odds Ratio (95%
Confidence Interval) P-Value
Age 1.000 (0.954-1.048) .988
Sex male versus female 1.799 (0.464-6.982) .396
Underlying disease lymphoid malignancy versus others 1.312 (0.388-4.443) .662
Disease status nonearly versus early 1.385 (0.393-4.876) .612
Conditioning regimen Reduced intensity versus myeloabrative 2.491 (0.707-8.777) .155
Stem cell source non-CB 1(referrence) – 1(referrence) –
CB (previous HSCT 2) 1.052 (0.119-9.313) .964 1.052 (0.119-9.313) .964
CB (previous HSCT +) 13.58 (3.447-53.52) <.001 13.58 (3.447-53.52) <.001
HLA mismatched versus matched 1.933 (0.542-6.889) .309
GVHD prophylaxis CI alone 1(referrence) –
CI plus sMTX 0.197 (0.035-1.107) .065
CI plus MMF 2.800 (0.427-18.38) .283
GVHD indicates graft-versus-host disease; CB, cord blood; HSCT, hematopoietic stem cell transplantation; MTX, methotrexate; MMF, mycophenolate
mofetil; CI, calcineulin-inhibitor.
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cases of CIPS have been reported for patients
undergoing HSCT [18,19,36-39]. Moreover, in our
study, 11 of 13 patients with HHV6-associated en-
cephalitis/myelitis developed CIPS-like dysesthesia
and/or pruritus. Although CI concentrations in these
patients were maintained within the targeted ranges
and reduction in concentrations was ineffective,
HHV6 DNA was directly detected in CSF samples
and administration of antiviral agents improved their
symptoms, indicating the relation of the symptoms
to the reactivation of HHV6. We found that 7 cases
that developed CIPS following HSCT have been re-
ported to date [18,19,36-39]; 3 developed CIPS after
UCBT, and 4 developed CIPS after a second HSCT:
2 for UCBT and 2 for BMT, respectively. In
addition, Kida et al. [38] showed that no possible cases
of CIPS were observed among 189 allogeneic BMT
and 65 allogeneic PBSCT recipients, whereas 2 of 34
cases that underwent UCBT developed CIPS. As
shown in our study, patients who receive UCBT or
a second HSCT have a high risk of occurrence of
HHV6-associated encephalitis/myelitis. Based on
these observations, we hypothesize that HHV6 reacti-
vation might contribute to aggravation of CIPS, and
therefore, CIPS might be one of the early manifesta-
tions of HHV6-associated encephalitis/myelitis.
HHV6 reactivation, localized in the posterior horn
of the spinal cord, where signals for both itch and
pain sensations are transmitted via c-fibers or Ad-fibers
[40], may cause distinctive manifestations like CIPS.
Indeed, all 4 of the cases who only developed CIPS-
like dysesthesia and/or pruritus had positive results
for HHV6 in their CSF samples, but not for head
MRI (limbic encephalitis), and only 1 case with MRI
scanning of the spine (case #13) showed multiple ab-
normal T2-high lesions. Because HHV6-associated
encephalitis/myelitis and CIPS can often occur at 2
to 4 weeks posttransplantation, it is important to
make a differential diagnosis of these 2 syndromes.In summary, our results have clearly shown that 2
or more RIC-UCBT presents a high risk for the devel-
opment of HHV6-associated encephalitis/myelitis, al-
though there are the limitations of the retrospective
single center analysis. Earlier diagnosis of and inter-
vention for this complication with combination antivi-
ral therapy may provide prolonged survival and
neurologic benefits. Therefore, transplantation physi-
cians should be aware that CIPS-like dysesthesia and
pruritus might be early manifestations that correlate
with the reactivation of HHV6, especially for patients
who develop myelitis. These ‘‘high-risk’’ recipients
can be potential candidates for prophylactic adminis-
tration of antiviral agents in future investigations.ACKNOWLEDGMENTS
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